Serum metabolomics reveals the metabolic profile and potential biomarkers of ankylosing spondylitis
Molecular Omics · 25.06.2024 · 20 (8) · 505-516
DOI: 10.1039/d4mo00076e ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, online erschienen am 25.06.2024. Verfasst von Liuyan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Ningxia Medical University, 1160 Shenli Street, Yinchuan, 750004, China. maxueqin217@126.com. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Biomarkers, Metabolomics, Metabolome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Ningxia Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease that significantly impairs physical function in young individuals. However, the identification of radiographic changes in AS is frequently delayed, and the diagnostic efficacy of biomarkers like HLA-B27 remains moderately effective, with unsatisfactory sensitivity and specificity. In contrast to existing literature, our current experiment utilized a larger sample size and employed both untargeted and targeted UHPLC-QTOF-MS/MS based metabolomics to identify the metabolite profile and potential biomarkers of AS. The results indicated a notable divergence between the two groups, and a total of 170 different metabolites were identified, which were associated with the 6 primary metabolic pathways exhibiting a correlation with AS. Among these, 26 metabolites exhibited high sensitivity and specificity with area under curve (AUC) values greater than 0.8. Subsequent targeted quantitative analysis discovered 3 metabolites, namely 3-amino-2-piperidone, hypoxanthine and octadecylamine, exhibiting excellent distinguishing ability based on the results of the ROC curve and the Random Forest model, thus qualifying as potential biomarkers for AS. Summarily, our untargeted and targeted metabolomics investigation offers novel and precise insights into potential biomarkers for AS, potentially enhancing diagnostic capabilities and furthering the comprehension of the condition's pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Ningxia Medical University, 1160 Shenli Street, Yinchuan, 750004, China. maxueqin217@126.com.
- Fujian University of Traditional Chinese Medicine, No. 1, Huatuo Road, Minhoushangjie, Fuzhou 350122, China. chenjianyu122@163.com.
Förderung
- Natural Science Foundation of Ningxia Province
- National Natural Science Foundation of China
Zitieren
APA
Li, L., Ding, S., Wang, W., Yang, L., Wilson, G., Sa, Y., Zhang, Y., Chen, J., & Ma, X. (2024). Serum metabolomics reveals the metabolic profile and potential biomarkers of ankylosing spondylitis. Molecular Omics, 20(8), 505-516. https://doi.org/10.1039/d4mo00076e
Vancouver
Li L, Ding S, Wang W, Yang L, Wilson G, Sa Y, et al. Serum metabolomics reveals the metabolic profile and potential biomarkers of ankylosing spondylitis. Molecular Omics. 2024;20(8):505-516. doi:10.1039/d4mo00076e
BibTeX
@article{Li2024,
author = {Li, Liuyan and Ding, Shuqin and Wang, Weibiao and Yang, Lingling and Wilson, Gidion and Sa, Yuping and Zhang, Yue and Chen, Jianyu and Ma, Xueqin},
title = {Serum metabolomics reveals the metabolic profile and potential biomarkers of ankylosing spondylitis},
journal = {Molecular Omics},
year = {2024},
volume = {20},
number = {8},
pages = {505--516},
doi = {10.1039/d4mo00076e}
}
EUVIMED